Pharmaceuticals, Biotechnology and Life Sciences
Exscientia provided Tuesday an update on its pipeline prioritisation strategy designed to further strengthen the Company’s focus, investment and infrastructure on programmes of greatest potential for differentiation and value creation, outlinging strategy which will support continued investment into market-leading technology while maintaining cash runway well into 2026.
New cancer cases rose by 2.3 % compared to 2020, to reach 2.74 million in 2022. Similarly, cancer deaths went up by 2.4 % compared to 2020, according to the European Commission’s estimates published in the European Cancer Information System (ECIS).
Novartis announced Monday positive top-line results from the pre-specified interim analysis of the Phase III APPLAUSE-IgAN study (NCT04578834) at 9 months.
The EUCAIM consortium and the European Commission have the first public release of its platform, Cancer Image Europe, marking a major milestone in the project’s development and an exciting step towards achieving its vision and goals.
Arecor Therapeutics has decided to increase the number of subjects within its ongoing Phase I clinical trial of ultra-rapid, ultra-concentrated insulin candidate AT278, in line with the update provided within its Interim Results on 14 September.
Poolbeg Pharma, a clinical-stage biopharmaceutical company, said last week that further to its announcement on 19 September 2023, the oral opposition hearing scheduled by the European Patent Office (‘EPO’) relating to the challenge to the Company’s European patent (Immunomodulator I), has been cancelled.
A commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections, Basilea Pharmaceutica, said…
Futura Medical, a UK pharmaceutical company developing innovative sexual health products, has been granted allowance of its EU patent which…
OptiBiotix Health, a life sciences business developing compounds to tackle obesity, cardiovascular disease, diabetes and skincare, finished first half of trading with sales of £351k, compared to the year 2022 sales of the same period, of £119k, which is a 195% increase over, the company said in its unaudited results for the six months ended 30 June 2023.
Hemogenyx Pharmaceuticals, the Standard Listed biopharmaceutical group developing therapies designed to transform blood disease treatment, committed to progressing HEMO CAR-T to clinical trials as the its next step.